Company Overview and News
KITCHENER, Ontario, June 07, 2018 (GLOBE NEWSWIRE) -- Brick Brewing Co. Limited (TSX:BRB) (“Brick” or the “Company”) today announced that at the annual and special meeting of shareholders held yesterday (the “Meeting”), each of the six nominees listed in the management information circular dated May 4, 2018 were elected as directors of the Company. A total of 23,179,487 common shares or 65.63% of Brick’s issued and outstanding common shares were voted in connection with the Meeting.
Brick Brewing Co. Limited (“Brick” or the “Company”) (TSX: BRB), Ontario’s largest Canadian-owned brewery, today announced the introduction of Chudleigh’s Orchard Cider.
Waterloo Brewing, the trade name of Brick Brewing Co. Limited (“Brick” or the “Company”) (TSX: BRB), today announced some of the exciting plans they have for LandShark Lager this summer.
Waterloo Brewing, the trade name of Brick Brewing Co. Limited (“Brick” or the “Company”) (TSX: BRB), today announced it was awarded a SMART Green grant to support an investment in new beer pasteurization equipment that will further reduce the brewery’s already leading environmental footprint.
Waterloo Brewing, the trade name of Brick Brewing Co. Limited (“Brick” or the “Company”) (TSX: BRB), today announced it has made an investment in equipment to produce non-alcoholic beer and reinforce its strategy of regional brewer leadership.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to TSX:BRB / Brick Brewing J on message board site Silicon Investor.
|Brick Brewing - BRB.T||CBRB : CBR BREWING - OTC:BB|